CoNCERT Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata
CoNCERT Pharmaceuticals' latest press release shows exciting potential for CTP-543 to be a best-in-class treatment for alopecia areata.